The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Developing a safe and effective drug is important, but it’s only part of the picture.
For the therapeutic effect of a drug to be effective, it largely depends on the delivery system. A drug delivery system navigates the pharmaceutical compound of the drug to its target location in the body and controls the rate of its release.
Today’s drug delivery practices have dramatically changed over the last few decades and are anticipated to have greater changes in the near future.
DehydraTECH™ and its Potential Market Applications
Lexaria’s DehydraTECH™ improves how active pharmaceutical ingredients enter the bloodstream.
The technology has demonstrated the following results:
- 5-10x increase in bio-absorption
- Reduced time of onset from hours to minutes
- Masking of unwanted taste
- Lower overall dosing
- Reduces Drug Administration Costs
DehydraTECH™-processed formulations can be applied to different ingestible formats, such as tablets, capsules, food, beverages and oral suspensions.
Lexaria is currently evaluating the effectiveness of DehydraTECH™-processed formulations for multiple multibillion-dollar markets in several applied R&D programs:
In addition to these markets, the company recently announced new R&D programs for 2021 in four new markets:
In addition to the above R&D programs, Lexaria has strategic licensing and research collaboration agreements for oral nicotine delivery. The global tobacco market was estimated to be worth $818 billion in 2019.
A research collaboration is currently underway with British American Tobacco, and the company is in discussions with other tobacco and pharmaceutical companies.
About Lexaria
Lexaria Bioscience Corp. is a food biosciences company with proprietary technology for improved delivery of bioactive compounds.
The company operates a federally licensed, in-house research laboratory and is building a robust intellectual property portfolio with 19 patents granted internationally and over 50 patent applications pending around the world..
Lexaria operates four subsidiary companies to focus on its different commercial opportunities in their respective industries:
To learn more about Lexaria, you can visit its website here.
Lexaria Bioscience is a partner of Benzinga. The information in this article does not represent the investment advice of Benzinga or its writers.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
